Valuation : Nurix Therapeutics, Inc.

Market Cap 2.72B 2.34B 2.2B 2.01B 3.77B 259B 3.8B 26.06B 10.14B 131B 10.21B 9.99B 435B P/E 2026 *
16.7x
P/E 2027 * -14.7x
Enterprise Value 1.77B 1.53B 1.43B 1.31B 2.46B 169B 2.48B 16.98B 6.61B 85.53B 6.66B 6.51B 283B EV / Sales 2026 *
2.35x
EV / Sales 2027 * 15.2x
Free-Float
98.67%
Yield 2026 *
-
Yield 2027 * -
1 day-1.64%
1 week-1.87%
Current month+11.07%
1 month+11.07%
3 months+48.25%
6 months+63.06%
Current year+35.90%
1 week 25.17
Extreme 25.17
27.5
1 month 22.64
Extreme 22.635
28.23
Current year 14.01
Extreme 14.01
28.23
1 year 8.2
Extreme 8.195
28.23
3 years 4.22
Extreme 4.22
29.56
5 years 4.22
Extreme 4.22
37.42
10 years 4.22
Extreme 4.22
52.38
Manager TitleAgeSince
Chief Executive Officer 64 2014-09-17
Director of Finance/CFO 60 2016-02-29
Chief Tech/Sci/R&D Officer - 2019-07-31
Director TitleAgeSince
Director/Board Member 64 2014-09-17
Chairman 73 2019-07-31
Chairman 72 2024-05-19
Date Insider Type Main position Quantity % Market Cap. Importance
8/5/26 Exercice

Chief Technology Officer

13,068 0.0126%
8/4/26 Sell

Chief Financial Officer

-4,761 0.0046%
8/4/26 Sell

Chief Technology Officer

-4,111 0.0040%
Change 5-day change 1-year change 3-year change Capi.($)
-1.64%-1.87%+182.99%+203.29% 2.72B
-1.66%-4.96%+49.84%+88.43% 69.54B
-2.19%+1.32%+44.54%+88.38% 64.97B
-3.57%-4.24%+47.11%+5.60% 26.51B
+2.77%-1.74%-16.16%+456.51% 25.89B
-0.46%-9.94%+0.98%-15.98% 25.64B
-9.71%-0.36%+245.87%+377.68% 20.22B
-1.58%+0.47%+29.35%-19.62% 19.98B
-3.36%-7.58%+9.47%+535.81% 15.69B
+0.35%+0.16%+46.96%+144.04% 13.49B
Average -2.10%-3.52%+64.09%+186.41% 28.46B
Weighted average by Cap. -2.01%-3.48%+49.37%+146.12%

Financials

2026 *2027 *
Net sales 755M 650M 611M 557M 1.05B 71.87B 1.05B 7.24B 2.82B 36.44B 2.84B 2.77B 121B 121M 104M 97.63M 89.12M 167M 11.49B 169M 1.16B 450M 5.83B 453M 444M 19.29B
Net income 368M 317M 298M 272M 510M 35.03B 514M 3.53B 1.37B 17.76B 1.38B 1.35B 58.82B -174M -150M -141M -128M -241M -16.55B -243M -1.67B -648M -8.39B -653M -639M -27.78B
Net Debt -947M -816M -766M -699M -1.31B -90.14B -1.32B -9.08B -3.53B -45.71B -3.56B -3.48B -151B -885M -762M -716M -653M -1.23B -84.24B -1.24B -8.48B -3.3B -42.72B -3.32B -3.25B -141B
Logo Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, aimed at improving treatment options for patients with cancer and autoimmune diseases. The Company's wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. The Company's portfolio of targeted protein degraders of the B‑cell signaling protein BTK comprises bexobrutideg (NX‑5948) and zelebrudomide (NX‑2127). The Company's degradation inhibitor program includes NX-1607, an orally bioavailable inhibitor of CBL-B, an E3 ligase that regulates the activation of multiple immune cell types including T cells and NK cells. NX-1607 is targeted for immuno-oncology indications.
Employees
317
Date Price Change Volume
26-08-31 US$25.78 -1.64% 1,244,000
26-08-28 US$26.21 -2.47% 929,230
26-08-27 US$26.88 +0.62% 1,256,943
26-08-26 US$26.71 -0.89% 551,875
26-08-25 US$26.95 +2.59% 1,176,297
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
26.21USD
Average target price
33.93USD
Spread / Average Target
+29.47%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NRIX Stock